Sandoz’ Symjepi Set To Undercut Rivals
Sandoz has set a US launch price for its Symjepi epinephrine anaphylaxis treatment that is significantly below that of Mylan’s EpiPen and Teva’s generic.
You may also be interested in...
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
Sandoz is encouraging US doctors to write prescriptions for epinephrine that include its Symjepi pre-filled syringes, and not just for auto-injector devices, as it targets the retail sector.
Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.